Ace investor Vijay Kedia acquired a significant stake in Mahamaya Lifesciences through a block deal. He purchased nearly 9 lakh shares at Rs 140 each. This transaction highlights investor interest in the agrochemical firm. Mahamaya Lifesciences manufactures pesticide formulations and crop protection products. The company has shown strong financial growth recently. Its shares have performed well since their market debut.
ICICI Prudential AMCs Rs 10,600 crore IPO drew nearly Rs 3 lakh crore in bids, led by strong global and domestic institutional demand. Robust anchor participation underscored confidence, though valuation and OFS structure suggest a steady, not explosive, listing.
Nifty has slipped below 25,900, signalling short-term weakness, but its broader uptrend remains intact, says HDFC Securities Vinay Rajani. He has also flagged 26,060 as the key resistance for a bullish reversal and 25,700 as crucial support. A break below this level could turn the trend into a positional downtrend.
